JNJ241115C139000
- 0.00
- 0.000.00%
Johnson & Johnson Newsroom
Renaissance Tech Adds Micron, Exits Broadcom, Among Q3 Trades
Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower
Vaccines Makers Close Lower on Reports RFK Jr May Head HHS
Market Falls Thursday, Powell Said Fed Will Take Things Slow | Wall Street Today
Wolfe Research Upgrades Johnson & Johnson(JNJ.US) to Buy Rating, Raises Target Price to $190
Thursday Market Chills From Election Celebration | Live Stock
Express News | Johnson & Johnson - Nipocalimab Shows 77% Igg Reduction in Phase 2 Study
Express News | Nipocalimab Demonstrates Significant Clinical Improvement in Disease Activity and Igg Reduction in Phase 2 Sjögren's Disease Study
Express News | Johnson & Johnson Medtech Announces Strategic Agreement With Responsive Arthroscopy to Expand Sports Soft Tissue Solutions
Bitcoin Gets Closer to $100k Than Ever | Wall Street Today
Sector Update: Health Care Stocks Edge Lower Wednesday Afternoon
Johnson & Johnson Sues US Government Over Rebate Model in Drug Discount Program
Bitcoin Breaks Above $90k, Market Flat Wednesday | Live Stock
Texas Instruments and Other Overlooked Dividend Aristocrat Stocks -- Barrons.com
Disease activity improved by over 70%. johnson & johnson (JNJ.US) potential blockbuster monoclonal antibody recognized as a breakthrough therapy.
Johnson & Johnson (JNJ.US) announced recently that the US FDA has granted Breakthrough Therapy Designation (BTD) to its investigational antibody therapy nipocalimab targeting the neonatal Fc receptor (FcRn), for the treatment of adult patients with moderate to severe primary Sjögren's syndrome.
J&J Sues HHS Over 340B Hospital Drug-discount Program
J&J Sues U.S. Over Hospital Drug-Discounting Program -- WSJ
Tuesday Market Finally Slows Down, Takes a Post Veterans Day Breather | Live Stock
3M, UnitedHealth Share Losses Lead Dow's 115-Point Drop
Express News | Johnson & Johnson Medtech Receives Ide Approval for Ottava™ Robotic Surgical System